Real-World Effectiveness of Lipid-Lowering Medications on Outcomes after Stroke: Potential Implications of the New-User Design.

2022

Olaiya, Muideen T

Andrew, Nadine E

Dalli, Lachlan L

Ung, David

Kim, Joosup

Cadilhac, Dominique A

Wood, Peter

May, Janet

Clissold, Ben

Kilkenny, Monique F

Adherence

Bias

Mortality

Outcomes

Secondary prevention

Stroke

Journal Article

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

10.1159/000526071

Observational studies are increasingly being used to provide evidence on the real-world effectiveness of medications for preventing vascular diseases, such as stroke. We investigated whether the real-world effectiveness of treatment with lipid-lowering medications after ischemic stroke is affected by prevalent-user bias.

link

Neuroepidemiology 2022

Neuroepidemiology

1423-0208